Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. reduced its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 10.6% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,312,479 shares of the company’s stock after selling 155,723 shares during the period. Assenagon Asset Management S.A. owned approximately 2.49% of Stoke Therapeutics worth $16,130,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Stoke Therapeutics during the first quarter worth about $1,224,000. BNP Paribas Financial Markets increased its holdings in shares of Stoke Therapeutics by 86.2% during the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after purchasing an additional 6,636 shares in the last quarter. Chase Investment Counsel Corp acquired a new position in shares of Stoke Therapeutics in the 1st quarter valued at $279,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Stoke Therapeutics in the 1st quarter valued at $141,000. Finally, Vanguard Group Inc. boosted its holdings in Stoke Therapeutics by 4.1% during the first quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company’s stock worth $23,160,000 after buying an additional 67,052 shares in the last quarter.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK opened at $11.91 on Friday. Stoke Therapeutics, Inc. has a 1 year low of $3.35 and a 1 year high of $17.58. The firm has a market capitalization of $620.76 million, a PE ratio of -4.94 and a beta of 0.97. The business’s 50 day moving average price is $13.48 and its 200-day moving average price is $13.68.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.11. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The company had revenue of $4.83 million for the quarter, compared to analysts’ expectations of $3.33 million. As a group, analysts expect that Stoke Therapeutics, Inc. will post -2.1 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on STOK. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, August 8th. Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. Leerink Partners began coverage on Stoke Therapeutics in a research report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and set a $17.00 target price on shares of Stoke Therapeutics in a research note on Thursday, July 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, September 11th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $20.83.

Insider Buying and Selling

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the sale, the insider now owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 11.30% of the stock is currently owned by company insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.